Promimic AB (publ) (PRO.ST)
SEK 25.8
(-1.15%)
SEK 25.8
(-1.15%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 37.07 Million SEK | 128.63% |
| 2022 | 16.21 Million SEK | 100.99% |
| 2021 | 8.06 Million SEK | 44.78% |
| 2020 | 5.57 Million SEK | -2.98% |
| 2019 | 5.74 Million SEK | 47.29% |
| 2018 | 3.89 Million SEK | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 8.65 Million SEK | -15.26% |
| 2024 Q2 | 12.01 Million SEK | 38.8% |
| 2023 Q1 | 6.19 Million SEK | 6.43% |
| 2023 FY | 37.07 Million SEK | 128.63% |
| 2023 Q4 | 10.21 Million SEK | 1.79% |
| 2023 Q2 | 10.63 Million SEK | 71.67% |
| 2023 Q3 | 10.03 Million SEK | -5.61% |
| 2022 Q4 | 5.81 Million SEK | 16.92% |
| 2022 Q3 | 4.97 Million SEK | 41.04% |
| 2022 Q2 | 3.52 Million SEK | 86.47% |
| 2022 Q1 | 1.89 Million SEK | -46.31% |
| 2022 FY | 16.21 Million SEK | 100.99% |
| 2021 Q1 | 1.3 Million SEK | 0.0% |
| 2021 FY | 8.06 Million SEK | 44.78% |
| 2021 Q2 | 1.41 Million SEK | 8.28% |
| 2021 Q4 | 3.52 Million SEK | 92.88% |
| 2021 Q3 | 1.82 Million SEK | 29.39% |
| 2020 FY | 5.57 Million SEK | -2.98% |
| 2019 FY | 5.74 Million SEK | 47.29% |
| 2018 FY | 3.89 Million SEK | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Acarix AB (publ) | 6.24 Million SEK | -493.975% |
| ADDvise Group AB (publ) | 1.37 Billion SEK | 97.3% |
| ADDvise Group AB (publ) | 1.37 Billion SEK | 97.3% |
| Arcoma AB | 163.01 Million SEK | 77.26% |
| Bactiguard Holding AB (publ) | 203.99 Million SEK | 81.828% |
| BICO Group AB (publ) | 2.23 Billion SEK | 98.345% |
| Boule Diagnostics AB (publ) | 571.32 Million SEK | 93.512% |
| CellaVision AB (publ) | 677.29 Million SEK | 94.527% |
| Clinical Laserthermia Systems AB (publ) | 8.27 Million SEK | -348.084% |
| Chordate Medical Holding AB (publ) | 976.28 Thousand SEK | -3697.063% |
| C-Rad AB (publ) | 424.61 Million SEK | 91.27% |
| Duearity AB (publ) | 1.65 Million SEK | -2141.233% |
| Dignitana AB (publ) | 86.06 Million SEK | 56.927% |
| Episurf Medical AB (publ) | 10.3 Million SEK | -259.903% |
| Getinge AB (publ) | 31.82 Billion SEK | 99.884% |
| Scandinavian Real Heart AB (Publ) | - SEK | -Infinity% |
| Iconovo AB (publ) | 7.07 Million SEK | -423.714% |
| Integrum AB (publ) | 104.11 Million SEK | 64.396% |
| Luxbright AB (publ) | 854.69 Thousand SEK | -4237.199% |
| Mentice AB (publ) | 273.61 Million SEK | 86.452% |
| OssDsign AB (publ) | 112.15 Million SEK | 66.948% |
| Paxman AB (publ) | 210.11 Million SEK | 82.357% |
| Qlife Holding AB (publ) | 244 Thousand SEK | -15092.623% |
| SciBase Holding AB (publ) | 23.24 Million SEK | -59.475% |
| ScandiDos AB (publ) | 60.42 Million SEK | 38.655% |
| Sectra AB (publ) | 2.96 Billion SEK | 98.749% |
| Sedana Medical AB (publ) | 153.86 Million SEK | 75.908% |
| Senzime AB (publ) | 35.75 Million SEK | -3.681% |
| SpectraCure AB (publ) | 318 Thousand SEK | -11557.233% |
| Stille AB | 294.89 Million SEK | 87.429% |
| Vitrolife AB (publ) | 3.51 Billion SEK | 98.944% |
| Xvivo Perfusion AB (publ) | 597.54 Million SEK | 93.796% |